Biotechnology company Larkspur Biosciences has dosed the first volunteers in the Phase I study of its treatment for microsatellite stable (MSS), colorectal cancer (CRC) and other solid tumours. 

LRK-4189 is an oral, first-in-class targeted protein degrader of the lipid kinase PIP4K2C. The drug triggers multiple killing mechanisms in difficult-to-treat cancer cells but will now be evaluated in healthy volunteers. 

“Given the preclinical safety and measurable biomarkers of LRK-4189 activity, starting in healthy volunteers is the most direct way to understand its pharmacology and define a biologically meaningful dose,” said Catherine Sabatos-Peyton, CEO of Larkspur Biosciences. 

“This approach positions us to begin patient studies at dose levels that matter on day one. We look forward to sharing study progress next year.” 

The Phase I study is a single-ascending dose trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of LRK-4189 in volunteers. The United Kingdom-based study expects to enrol approximately 40 participants. The clinical programme and recruitment of healthy volunteers will be handled by Quotient Sciences. 

“While it’s been established that PIP4K2C is broadly expressed in many hard-to-treat cancers, including colorectal cancer, this pathway has been elusive to engage with therapeutically until now,” said Antoni Ribas, Professor of Medicine, Surgery, and Molecular Medical Pharmacology at the University of California Los Angeles (UCLA), Past President of the American Association for Cancer Research (AACR), and Larkspur advisor.   

“Larkspur’s data on LRK-4189 in preclinical models of cancer are compelling, and we’re looking forward to seeing the impact of this potential new approach on treating advanced solid tumours.” 

According to the American Cancer Society, approximately 150,000 cases of CRC are diagnosed annually in the US, with MSS CRC accounting for about 85% of all CRC cases. 

 

Bruno Quinney, Content Team, DDW